



RECEIVED

APR 23 2003

PATENT APPLICATION

Serial No. 10/031,509

Atty. Docket No. 702-020040

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit 1614

In re application of

Eric Paul KRENNING et al.

Serial No. 10/031,509

Filed May 21, 2002

Examiner Not Yet Assigned

INHIBITION OF RENAL UPTAKE OF
MOLECULES THAT ARE POTENTIALLY
DAMAGING FOR THE KIDNEY

Pittsburgh, Pennsylvania
April 17, 2003

INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents
Washington, D.C. 20231

Sir:

Pursuant to the requirements of 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants submit this Information Disclosure Statement together with a completed Form PTO/SB/08A.

This application is the United States national phase of PCT Application No. PCT/EP00/06917. The International Search Report dated February 1, 2001, for the underlying PCT Application identified the references listed on Form PTO/SB/08A. Copies of the International Search Report and the references listed on Form PTO/SB/08A are not being submitted with this Information Disclosure Statement as they were received by the United States

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231 on April 17, 2003.

Angela Sabatini

(Name of Person Mailing Paper)

Signature

04/17/03
Date

Patent and Trademark Office as indicated in the Notification Of Missing Requirements Under 35 U.S.C. 371 In The United States Designated/Elected Office (DO/EO/US), dated March 22, 2002.


Because this Information Disclosure Statement is being submitted before the mailing date of a first Office Action on the merits, it is timely under 37 C.F.R. §1.97(b)(3) and no fee is required.

The Commissioner of Patents and Trademarks is hereby authorized to charge any additional fees which may be required to Deposit Account No. 23-0650. One (1) original and two (2) copies of this Information Disclosure Statement are enclosed.


Respectfully submitted,

WEBB ZIESENHEIM LOGSDON
ORKIN & HANSON, P.C.

By



Barbara E. Johnson
Registration No. 31,198
Attorney for Applicants
700 Koppers Building
436 Seventh Avenue
Pittsburgh, PA 15219-1818
Telephone: (412) 471-8815
Facsimile: (412) 471-4094
E-mail: webblaw@webblaw.com



Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



RECEIVED

APR 23 2003

TECH CENTER 1600/2900

Please type a plus sign (+) inside this box → ☐Approved for use through 10/31/2001. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/031,509		
		Filing Date	05/21/2002		
		First Named Inventor	Eric Paul Krenning		
		Group Art Unit	1614		
		Examiner Name	Not Yet Assigned		
Sheet	2	of	2	Attorney Docket Number	0702-020040

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cite and/or country where published.	T ²
		HAMMOND, P.J. et al., "Amino Acid Infusion Blocks Renal Tubular Uptake Of An Indium-Labelled Somatostatin Analogue", British Journal of Cancer, GB, London, Vol. 67, June 1993, pp. 1437-1439	
		BEHR T.M. et al. "Reduction of the Renal Uptake of Radiolabeled Monoclonal Antibody Fragments By Cationic Amino Acids And Their Derivatives", Cancer Research, Amer. Assoc. For Cancer Research, Vol. 55, No. 17, (1995), pp. 3825-3834	
		PIMM M. V. et al. "Prevention of Renal Tubule Re-Absorption of Radiometal (indium-111) Labelled Fab Fragment of a Monoclonal Antibody in Mice by Systemic Administration of Lysine"	
		BEHR T. M. et al "Reduction of Renal Uptake of Monoclonal Antibody Fragments By Amino Acid Infusion", J. Nucl. Med., Vol. 37, No. 5 (1996), pp. 829-833	
		KRENNING E. P. et al. "Radiolabelled Somatostatin Analogue(s) For Peptide Receptor Scintigraphy And Radionuclide Therapy", Annals of Oncology, Vol. 10, No. Suppl 2 (1999), pp. s23-s29	
		BEHR T. M. et al. "Improved Prospects For Cancer Therapy With Radiolabeled Antibody Fragments And Peptides?", J. Nucl. Med. Vol. 37, No. 5, (1996), pp. 834-836	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.